Pantoprazole Brown & Burk Uk (Pantoprazole Sodium Sesquihydrate)

Pantoprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related conditions.

• Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis.
• Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition.

• Pantoprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells. By binding covalently to the pump in its active state, it blocks the final step of acid production, leading to a sustained increase in gastric pH and reduced acidity in the stomach.

Adverse reactions to pantoprazole are generally mild to moderate, but serious events can occur.

Common Side Effects

• Headache: mild, transient headache reported in clinical use.
• Diarrhea: loose stools occurring during early treatment.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild discomfort in the stomach region.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.
• Clostridioides difficile infection: persistent watery diarrhea with abdominal cramping.
• Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat.
• Bone fractures: increased risk with long‑term use, especially in the elderly.
• Liver enzyme elevation: signs of hepatic stress in blood tests.
• Acute interstitial nephritis: kidney inflammation presenting with reduced urine output.

Before initiating therapy, consider patient‑specific factors and monitor appropriately.

• Assess renal function: dose adjustment may be needed in severe impairment.
• Evaluate hepatic status: use caution in moderate to severe liver disease.
• Review concomitant medications: potential for altered absorption of drugs requiring acidic pH.
• Monitor long‑term users: watch for bone density loss and magnesium deficiency.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Pantoprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Antifungal agents (e.g., ketoconazole, itraconazole): markedly reduced absorption.
• HIV protease inhibitors (e.g., atazanavir): decreased plasma concentrations.
• Clopidogrel: reduced activation leading to diminished antiplatelet effect.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR, requiring closer monitoring.
• Methotrexate (high dose): possible accumulation and toxicity.
• Digoxin: slight increase in serum levels, monitor for signs of toxicity.